Auto-immune risks of hepatitis B vaccination: a clue on biological plausibility. (PDF Girard)
Posted: Fri Mar 23, 2007 4:19 pm
This includes Rhuematoid Arthritis (an auto-immune disease)
Symptoms will show in susceptible area
Some MS, some Juvenile Rheumatoid Arthritis, some lupus, and on and on
Auto-immune risks of hepatitis B vaccination: a clue on biological
plausibility. (PDF Girard)
PDF FILE of article
http://www.nccn.net/~wwithin/girardhepbvax.pdf
Auto-immune risks of hepatitis B vaccination: a clue on biological
plausibility.
Dr Marc Girard (Versailles, France), a specialist in the side-effects of
drugs, was commissioned as a medical expert witness by French courts, and
spent thousands of hours evaluating the problems related to hepatitis B
vaccination. Although most of his results remain confidential by court
order, Dr. Girard recently disclosed evidence demonstrating that this
specific vaccine is remarkable by the unusual frequency, severity and
variety of its adverse events (Autoimmun Rev 2005; 4: 96-100). He also
reported that studies performed by the French health authorities and
revealing clear auto-immune risks have remained unpublished.
Apparently concerned by the strength of the clinical and epidemiological
evidence presented, leading experts in auto-immunity wrote an accompanying
editorial challenging the author to provide credible mechanisms for these
toxic effects (Autoimmun Rev 2005; 4: 79-81).
In a publication now in press in Medical Hypotheses and currently available
on line, Drs. Comenge and Girard discuss the toxicity spectrum of the
Hepatitis B vaccine and its clinical manifestations, namely: 1)
vaccine-induced findings of hepatitis B (as predicted quite earlier during
the development of the vaccine); 2) central demyelinating diseases, the
epidemiological evidence of which is beyond reasonable doubt, and which
might be triggered by minute amounts of a viral polymerase protein
contaminating the vaccine.
Because of the significance and scope of these observations, Dr. Girard
suggests that even in highly-endemic countries, the risk/benefit ratio of
this unusually toxic vaccine must be carefully re-assessed.
Important new study by Marc Girard and Yannick Comenge regarding the safety
of Hepatitis B vaccine (currently proposed by the British Medical
Association for addition to the UK infant schedule).
PDF FILE of article
http://www.nccn.net/~wwithin/girardhepbvax.pdf
Multiple sclerosis and hepatitis B vaccination:
Adding the credibility of molecular biology
to an unusual level of clinical and
epidemiological evidence
Yannick Comenge
a
, Marc Girard
b, *
Received 29 July 2005; accepted 1 August 2005
Summary In spite of a huge number of reports of severe hazards after
injection of hepatitis B vaccine (HBV), the
issue is regularly raised that no mechanism is available for the
development of central demyelinating disorders such as
multiple sclerosis (MS). A number of convergent facts, however, suggests
that the manufacturing process could
introduce HBV polymerase as a contaminant, and then trigger an auto-immune
process against myelin in some
vaccinated subjects. Of great significance, this hypothesis is likely to
give the missing link to account for the
considerable body of clinical and epidemiological evidence documenting
that, for a drug used with a preventive
purpose, HBV has an unusual potential to induce central neurological
disorders amongst others unwanted side-effects.
c 2005 Elsevier Ltd. All rights reserved.
Symptoms will show in susceptible area
Some MS, some Juvenile Rheumatoid Arthritis, some lupus, and on and on
Auto-immune risks of hepatitis B vaccination: a clue on biological
plausibility. (PDF Girard)
PDF FILE of article
http://www.nccn.net/~wwithin/girardhepbvax.pdf
Auto-immune risks of hepatitis B vaccination: a clue on biological
plausibility.
Dr Marc Girard (Versailles, France), a specialist in the side-effects of
drugs, was commissioned as a medical expert witness by French courts, and
spent thousands of hours evaluating the problems related to hepatitis B
vaccination. Although most of his results remain confidential by court
order, Dr. Girard recently disclosed evidence demonstrating that this
specific vaccine is remarkable by the unusual frequency, severity and
variety of its adverse events (Autoimmun Rev 2005; 4: 96-100). He also
reported that studies performed by the French health authorities and
revealing clear auto-immune risks have remained unpublished.
Apparently concerned by the strength of the clinical and epidemiological
evidence presented, leading experts in auto-immunity wrote an accompanying
editorial challenging the author to provide credible mechanisms for these
toxic effects (Autoimmun Rev 2005; 4: 79-81).
In a publication now in press in Medical Hypotheses and currently available
on line, Drs. Comenge and Girard discuss the toxicity spectrum of the
Hepatitis B vaccine and its clinical manifestations, namely: 1)
vaccine-induced findings of hepatitis B (as predicted quite earlier during
the development of the vaccine); 2) central demyelinating diseases, the
epidemiological evidence of which is beyond reasonable doubt, and which
might be triggered by minute amounts of a viral polymerase protein
contaminating the vaccine.
Because of the significance and scope of these observations, Dr. Girard
suggests that even in highly-endemic countries, the risk/benefit ratio of
this unusually toxic vaccine must be carefully re-assessed.
Important new study by Marc Girard and Yannick Comenge regarding the safety
of Hepatitis B vaccine (currently proposed by the British Medical
Association for addition to the UK infant schedule).
PDF FILE of article
http://www.nccn.net/~wwithin/girardhepbvax.pdf
Multiple sclerosis and hepatitis B vaccination:
Adding the credibility of molecular biology
to an unusual level of clinical and
epidemiological evidence
Yannick Comenge
a
, Marc Girard
b, *
Received 29 July 2005; accepted 1 August 2005
Summary In spite of a huge number of reports of severe hazards after
injection of hepatitis B vaccine (HBV), the
issue is regularly raised that no mechanism is available for the
development of central demyelinating disorders such as
multiple sclerosis (MS). A number of convergent facts, however, suggests
that the manufacturing process could
introduce HBV polymerase as a contaminant, and then trigger an auto-immune
process against myelin in some
vaccinated subjects. Of great significance, this hypothesis is likely to
give the missing link to account for the
considerable body of clinical and epidemiological evidence documenting
that, for a drug used with a preventive
purpose, HBV has an unusual potential to induce central neurological
disorders amongst others unwanted side-effects.
c 2005 Elsevier Ltd. All rights reserved.